Open Access
CC BY-NC-ND 4.0 · Eur J Dent 2017; 11(04): 417-421
DOI: 10.4103/ejd.ejd_191_17
Original Article
Dental Investigation Society

Evaluation of intracanal acetazolamide in late reimplanted rat teeth

Camila Paiva Perin
1   Departament of Endodontics Universidade Tuiuti do Paraná Curitiba, Paraná, Brazil
,
Vula Papalexiou
1   Departament of Endodontics Universidade Tuiuti do Paraná Curitiba, Paraná, Brazil
,
Aline Cristina Batista Rodrigues Johann
1   Departament of Endodontics Universidade Tuiuti do Paraná Curitiba, Paraná, Brazil
,
Natanael Henrique Ribeiro Mattos
1   Departament of Endodontics Universidade Tuiuti do Paraná Curitiba, Paraná, Brazil
,
Fernando Henrique Westphalen
1   Departament of Endodontics Universidade Tuiuti do Paraná Curitiba, Paraná, Brazil
,
Vânia Portela Ditzel Westphalen
1   Departament of Endodontics Universidade Tuiuti do Paraná Curitiba, Paraná, Brazil
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
01. Oktober 2019 (online)

Preview

ABSTRACT

Objective: The aim of this study was to evaluate the use of acetazolamide combined with different agents as intracanal medication in late reimplanted rat teeth. Materials and Methods:In 100 Wistar rats, divided into 5 groups of 20, one of the following medications was used: Acetazolamide liquid (AL); AL with calcium hydroxide powder (ALHC); acetazolamide powder with AL; acetazolamide powder with physiological solution; and calcium hydroxide with physiological solution (control). At 30 and 60 days after reimplantation, the animals were sacrificed, tissues were processed, and cuts were stained with hematoxylin and eosin. An optical microscope was used to determine the following: percentage of inflammatory root resorption (RRI); percentage of substitute root resorption (RRS); and presence of ankylosis. The data obtained was submitted for statistical analysis. Results: Group ALHC had a significantly higher RRS than the control group at 60 days (P = 0.01). Group AL showed significantly less ankylosis than the other groups, including the control, at 30 days. AL showed results similar to those of the control group with respect to RRS. Conclusion:Acetazolamide has the potential to be an effective intracanal medication.